Protocol for the Tessa Jowell BRAIN MATRIX Platform Study

作者：Colin Watts, Joshua S. Savage, Amit Suresh Patel, Rhys Mant, Victoria Wykes, Ute Pohl, Helen Bulbeck, John Richard Apps, Rowena Sharpe, Gerard Thompson, Adam D. Waldman, Olaf Ansorge, Lucinda Jane Billingham · 发表于：BMJ Open · 年份：2022 · DOI：10.1136/bmjopen-2022-067123 · 被引用次数：12 · 研究领域：Glioma Diagnosis and Treatment、Brain Tumor Detection and Classification、Radiomics and Machine Learning in Medical Imaging

INTRODUCTION: Gliomas are the most common primary tumour of the central nervous system (CNS), with an estimated annual incidence of 6.6 per 100 000 individuals in the USA and around 14 deaths per day from brain tumours in the UK. The genomic and biological landscape of brain tumours has been increasingly defined and, since 2016, the WHO classification of tumours of the CNS incorporates molecular data, along with morphology, to define tumour subtypes more accurately. The Tessa Jowell BRAIN MATRIX Platform (TJBM) study aims to create a transformative clinical research infrastructure that leverages UK National Health Service resources to support research that is patient centric and attractive to both academic and commercial investors. METHODS AND ANALYSIS: The TJBM study is a programme of work with the principal purpose to improve the knowledge of glioma and treatment for patients with glioma. The programme includes a platform study and subsequent interventional clinical trials (as separate protocols). The platform study described here is the backbone data-repository of disease, treatment and outcome data from clinical, imaging and pathology data being collected in patients with glioma from secondary care hospitals. The primary outcome measure of the platform is time from biopsy to integrated histological-molecular diagnosis using whole-genome sequencing and epigenomic classification. Secondary outcome measures include those that are process centred, patient centred and framewor...